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ABSTRACT
Colorectal cancer (CRC) is one of the deadliest types of cancer in the US due to
its high incidence and mortality rates. Detection of CRC in the early stages through
available screening tests increases the patient's survival chances. In this study, we
investigate the cost-effectiveness of a wide variety of multi-modal CRC screening
policies. More specifically, we develop a Monte Carlo simulation framework to model
the CRC natural history and preventive interventions. Age-specific and size-specific
progression rates of adenomatous polyps are estimated using an innovative active
learning method. Specifically, we develop a decision tree model to estimate size-specific
and age-specific adenoma progression and regression rates. Compared to traditional
methods, the proposed calibration process expedites the searching of the model parameter
space significantly. CRC age-specific incidence rates and CRC stage distribution are the
two output measures used in the calibration process. Seventy-eight CRC screening
policies are applied to a cohort of U.S. male population using the simulation model and
compared in terms of expected Quality Adjusted Life Years (QALY) and costs. Eleven
policies are identified as efficient frontier policies. Among these 9 are identified as costeffective at the willingness to pay (WTP) threshold of $50,000. Fecal Occult Blood Test
(FOBT) biennially in conjunction with one time Colonoscopy at 60, FOBT biennially
along with one time Colonoscopy at 50, Fecal Immunochemical Test (FIT) biennially in
conjunction with two times Flexible Sigmoidoscopy (FS) at 60 and 65. FIT biennially
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with one time Colonoscopy at 65, Colonoscopy at 50, 60 and 70, FOBT biennially along
with two times Colonoscopy at 55 and 65, FOBT annually with 2 times FS at 70 and 75,
FOBT annually in conjunction with FS at 50 and 55, and FIT biennially along with FS
every 5 years are the nine identified cost-effective policies.
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CHAPTER 1
INTRODUCTION
Colon and rectal cancer are often grouped together and called colorectal cancer
(CRC) since they have many features in common (American Cancer Society 2018). It is
estimated that in 2018, more than 140,000 people are diagnosed with CRC and more than
50,000 patients are dead from CRC (National Cancer Institute 2018a). More than 8% of
cancer incidences and deaths are estimated to be CRC related (National Cancer Institute
2018a). According to the Surveillance, Epidemiology, and End Result (SEER) program
1975-2015 review, between 2011 and 2015, approximately 9% of all new cancer cases
are CRC and about 9% of all cancer-related deaths are due to CRC, making it the second
deadliest cancer and the fourth most common cancer among all different types of cancer.
CRC starts with a polyp in the innermost layer of the colon or rectum and may grow
through other layers of the colon if not detected and treated (American Cancer Society
2018). There are two main types of polyp in the colon and rectum. Adenomatous polyps,
also called adenomas, are the type which can develop to cancer. The second type of
polyps is hyperplastic and inflammatory polyps which generally do not develop into
cancer (American Cancer Society 2018). While in the wall of the colon or rectum, cancer
cells may spread to adjacent lymph nodes or distant body parts through the blood or
lymph vessels. Stages of CRC are based on how deep they have grown into the colon or
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rectum wall or how far they have traveled outside of their organ of origin (American
Cancer Society 2018).
CRC mortality risk can be reduced through detection of cancer in early stages
when there is a higher survival chance. The overall five-year surveillance rate for CRC is
64.6%. This ratio for cases who are diagnosed in the localized and distant stage is 90%
and 13.9%, respectively. These ratios show the importance of detecting CRC in an early
stage. Currently, there are several early CRC detection screening tests available, such as
Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Flexible
Sigmoidoscopy (FS), and colonoscopy (Lansdorp-Vogelaar et al. 2011). These tests vary
in different features. Sigmoidoscopy and colonoscopy use a camera on a flexible tube
introduced through the anus to examine the colon and rectum for abnormal growths.
These tests are categorized into visual (structural) exams since they look at the structure
inside the colon and rectum for any abnormal areas that might be cancer or adenomas.
Sigmoidoscopy is performed on an alert patient and reaches at most the first third of the
large colon. Any polyps detected are recorded (and maybe removed and biopsied) and the
patient is generally referred for colonoscopy. Colonoscopy is the most aggressive and
expensive procedure performed on a sedated patient, and permits an examination of the
entire colon. During a colonoscopy, any suspicious polyps can be removed, which may
prevent cancer occurrence in the future (National Cancer Institute 2018b). FIT and FOBT
are stool-based tests and look for evidence of occult (hidden) blood in the stool. FIT
reacts to the part of the human hemoglobin protein, found in red blood cells. FOBT
detects occult blood in the stool through a chemical reaction, in a different way than FIT.
Neither FIT nor FOBT can specify if the blood is from the colon or other parts of the
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digestive tract since the blood can be from cancers or polyps or some other non-CRCrelated causes (American Cancer Society 2018). Therefore, a positive FIT or FOBT
requires a follow-up colonoscopy. One of the weaknesses associated with FIT and FOBT
is low specificity which results in higher false positives in test results. The associated
high false positive results increase the number of unnecessary colonoscopy tests (Lejeune
et al. 2014). To avoid false positive results, patients are required to follow some dietary
restrictions before FOBT tests. However, no dietary restriction is required before FIT
(American Cancer Society 2018). Stool-based tests are usually associated with low costs
which come with lower sensitivity as well (Knudsen et al. 2016; Prakash et al. 2017).
Currently, there is no evidence on which CRC screening policy is most effective
in early detection of CRC cases at the population level (Prakash et al. 2017; Stracci et al.
2014). A review of the current literature on CRC screening shows that clinicians need
more guidance to choose the best screening policy for their patients based on the patient's
different risk factors such as age, sex, and health condition. This is also manifested as a
result of the differences in CRC screening tests and thereby different utility levels of
these tests for patients with different risk factors. Multi-modal screening policies can
benefit patients by providing more diverse screening options with different sensitivity
and specificity based on the patient's risk. For example, a screening strategy which
recommends stool-based tests at younger ages and colonoscopy at older ages can be a
potential improvement for a low-risk patient compared to only colonoscopy screening
policy since the stool-based tests are less aggressive (Dinh et al. 2013). Table 1-1
presents the in-practice CRC screening guidelines recommended by different health
agencies in the US. It includes the most recent in-practice screening policies provided by
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the United States Preventive Service Task Force (USPSTF), the US Multi-Society Task
Force (USMSTF), and the American Cancer Society (ACS). All three agencies
recommend patients start screening at age 50. None of the three health agencies
recommend individuals older than 75 to undergo any screening unless under special
circumstances. Among the nine policies listed in Table 1-1, only one policy
recommended by the USPSTF is a multi-modal policy recommending a mixture of
screening tests.
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Table 1-1: In-practice screening policies recommended by different health agencies.
Agency

Age

50-75

USPSTF

76-85

85+

50-75

ACS
76-85

85+

USMSTF

50-75

Recommended Test

Frequency

FOBT
Colonoscopy
FS-FOBT

Annually
Every 10 years
FS every 5 years
along with FOBT
every 3 years

The USPSTF recommends against routine
screening for colorectal cancer in adults 76 to
85 years of age. There may be considerations
that support colorectal cancer screening in an
individual patient.
The USPSTF recommends against screening
for colorectal cancer in adults older than age
85 years.
FIT
FOBT
Multi-target stool DNA test
Colonoscopy
CT Colonography
FS
The ACS recommends that clinicians
individualize CRC screening decisions for
individuals based on patient preferences, life
expectancy, health status, and prior screening
history
The ACS recommends that clinicians
discourage individuals over age 85 from
continuing CRC screening
Colonoscopy
FIT
CT Colonography
FIT-fecal DNA test
FS
Capsule colonoscopy

NA

NA
Annually
Annually
Every 3 years
Every 10 years
Every 5 years
Every 5 years

NA

NA
Every 10 years
Annually
Every 5 years
Every 3 years
Every 5 years
Every 5 years
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1.1

Active Learning as a Simulation Calibration Tool

Simulation models must be adequately calibrated to ensure a valid representation
of the actual system. A review of the literature shows that more than 85% of the cancer
simulation models used a calibration method to adjust their output (Stout et al. 2009).
Trial and error, random sampling, and grid search are some of the popular approaches
used (Stout et al. 2009). Although these methods work for simple simulation models, they
are not efficient enough or even practical for more complex models with a large
parameter set. Grid search and random search, specifically, conduct an extensive search
in the parameters solution space. This makes these methods very intriguing for smaller
simulation models, but very time-consuming and sometimes impractical for more
complex simulation models. The extensive search of the parameter combinations can be
avoided by identifying smaller neighborhoods which are more likely to contain the
"optimum" combinations. Hence, machine learning methods such as decision tree
algorithms or regression models can be used to search the parameter set more efficiently
(Cevik et al. 2016). Active learning (also known as query learning) is considered as a
sub-field of machine learning and, more generally, artificial intelligence. As it is shown
in Figure 1-1, the key concept of active learning is that the learning algorithm is able to
interactively query the user (or some other information source) to obtain the desired
outputs at new data points. This results in an improved performance with less training
(Russell and Norvig 2016). Supervised learning is the machine learning task of learning a
function that maps an input to an output based on sample input-output pairs (Russell and
Norvig 2016). Each example is a pair consisting of an input object (typically a vector)
and the desired output value. A supervised learning algorithm analyzes the training data
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and produces a function, which can be used for mapping new examples. An optimal
scenario will allow for the algorithm to correctly determine the class labels for unseen
instances. This requires the learning algorithm to generalize from the training data to
unseen situations in a reasonable way (Mohri et al. 2012). For any supervised learning
system to perform well, it must often be trained on a large set of labeled instances.
Sometimes these labels come at little or no cost, but for many other sophisticated
supervised learning tasks, labeled instances are very difficult, time-consuming, or
expensive to obtain. Therefore, the ability to learn with less data is considered a desirable
property for learning algorithms (Settles 2012). Active learning algorithms enable the
calibration models to efficiently choose a better combination of parameters to guide the
model outputs to the output measure targets in clinical reports. The idea of the use of
active learning in simulation calibration process was first introduced by Cevik et al.
(2016). In that study authors used active learning to calibrate a breast cancer simulation
model developed at the University of Wisconsin. A small set of evaluated parameters are
labeled with a scoring approach to train an artificial neural network as a prediction
model. The prediction model is used to constrain parameter combinations to a smaller
neighborhood where parameters are more likely to produce the desired output.
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Figure 1-1: Learning cycle of a schematic supervised active learning model (City University
of Hong Kong 2018).

In this study, we investigate the cost-effectiveness of a wide range of multi-modal
CRC screening policies. Moreover, we conduct a comprehensive evaluation of in-practice
policies listed in Table 1-1. The alternative policies are compared with the in-practice
policies. To the best of our knowledge, current studies on CRC screening policy costeffectiveness analysis are limited in the extent of the details in capturing the disease
dynamics in pre-cancerous stages. In this study, age-specific and stage-specific precancerous progression and regression rates are estimated using an innovative active
learning approach. More specifically, the main contributions of this study are as follows.
1) We developed a detailed CRC natural history model which captures the dynamics of
pre-cancerous states as well as the cancer states. The proposed model incorporates three
different adenomatous polyps’ sizes and the possibility of adenomas’ regression. The
proposed detailed model enables us to study the disease dynamics and the impact of
possible intervention more precisely. 2) We estimated the parameters of the detailed
proposed natural history model using innovative active learning methods. Currently, there
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is no detailed data available to estimate age and stage specific transition rates in the precancerous states. As a result, the existing models use simplified models in characterizing
the CRC natural history which may introduce some bias in the corresponding analysis. In
this study, using active learning, specifically decision trees, we devise a more efficient
and faster calibration process to estimate the detailed natural history model parameters. 3)
We investigated the cost-effectiveness of a variety of CRC screening policies. Screening
policies are generated based on different screening tests’ features and the disease
dynamics in the average-risk population. Policies are designed as a combination of stoolbased and visual screening tests to take advantage of both types of tests.
This thesis is structured as follows. In CHAPTER 2 we present a review of the
literature on the effectiveness and cost-effectiveness analysis of CRC screening
strategies. In CHAPTER 3, the proposed CRC natural history and intervention simulation
models are presented. The proposed method for simulation calibration is also presented
in this section. Parameters estimation details are discussed in CHAPTER 4. Numerical
results are presented in CHAPTER 5 followed by the conclusion presented in CHAPTER
6.

CHAPTER 2
LITERATURE REVIEW
A review of the studies on the effectiveness/cost-effectiveness of CRC screening
policies is given by Lansdorp-Vogelaar et al. (2011), Patel and Kilgore (2015), and
Pignone et al. (2002). Table 2-1 lists studies that are most relevant to ours and their
models’ specifications. Currently, most of the recommended screening guidelines,
suggested by recent studies and in-practice screening policies, are uni-modal (Dinh et al.
2013; Sharaf and Ladabaum 2013). A partially observed Markov chain (POMC) model is
developed by Li et al. (2014) to evaluate the cost-effectiveness of colonoscopy and
determine the effect of the length of the intervals between colonoscopy tests. They
developed a natural history model which includes three pre-cancerous states (small,
medium, and large adenomas). Cancer states are categorized into localized, regional, and
distant cancers. All three cancerous states are divided into clinical and preclinical states.
However, adenoma regression is not included in the proposed model. Data are taken from
literature and the model is calibrated against clinical data of a specific group of patients.
Their results show that colonoscopy intervals have a significant impact on the costeffectiveness of the screening policies. Vijan et al. (2007) has also developed a Markov
model to evaluate the performance of three uni-modal screening policies: CT
colonography every 5 years, CT colonography every 10 years and colonoscopy every 10
years. Cancer states are similar to the model presented by Li et al. (2014); however, this
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model divides the pre-cancerous states based on the risk of becoming cancer into low-risk
polyps and high-risk polyps. Transition rates from high-risk adenoma to cancer are
assumed to be 100%. No calibration method is used and the possibility of adenomatous
polyps’ regression and symptomatic cancers are not considered in the proposed model.
Screening policies are compared based on diagnostic accuracy in detecting polyps and
cancer tissues. They found that CT colonography every 5 or 10 years is cost-effective
compared to no-screening policy. However, colonoscopy every 10 years between the age
of 50 and 80 is still the most cost-effective policy. Pil et al. (2016) developed a Markov
model to analyze the cost-effectiveness of biennial FOBT for both men and women aged
56 to 74. Incremental cost-effectiveness ratio (ICER), when compared with no-screening
policy, is used to evaluate the policy. They adopted the tumor, node, and metastasis
(TNM) tumor classification system for CRC modeling. TNM is a CRC stage
classification system presented by the American Joint Committee on Cancer (AJCC).
Adenomatous polyps in the proposed model are assumed to be low-risk or high-risk.
Results show that for the tested policies, the probability of being cost-effective is 100%
for men and 97% for women. This study does not incorporate the possibility of adenoma
regression and symptomatic cancer in the CRC modeling. Van Rossum et al. (2011)
developed a Markov model to evaluate the cost-effectiveness of one round of FOBT
compared to one round of FIT for patients aged between 50 and 75. Similar to Pil et al.
(2016), they adopted the TNM classification system for cancer states modeling and
assumed that there is only one pre-cancerous state as advanced adenoma. No calibration
method is discussed in Pil et al. (2016) and Van Rossum et al. (2011). However, they
performed sensitivity analysis to assess the outputs’ sensitivity to changes in the value of
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the parameters with a high level of uncertainty. The result shows that among the tested
policies, FIT outperforms FOBT while both policies are shown to be cost-effective versus
no-screening. Lee and Park (2016) developed a Markov model to evaluate the costeffectiveness of annual FOBT and its effect on health disparity compared to no-screening
policy. They used a very simplified natural history model including only three states:
polyp, early cancer, and advanced cancer. The proposed model used in this study does
not incorporate the effect of symptomatic cancer in the natural history, and there is no
calibration process to reduce the error of the Markov model against epidemiological
reports. The Atkinson ICERs (ICER adjusted by the Atkinson Inequality Index (Atkinson
1970)) are calculated based on the gained QALYs, total screening, and treatment costs to
evaluate the screening policies. Hypothetical participants are tested via different policies
between age 50 and 80. Results show that the annual FOBT between 50 and 80 is costeffective and has a higher health disparity compared to no-screening. Prakash et al.
(2017) developed a micro-simulation model based on Colon Modeling Open Source Tool
(CMOST) to calculate the optimal timing of colonoscopy tests. The proposed microsimulation model calculates the impact of different screening policies and their
incorporated costs. CMOST models the natural history of CRC providing automated
calibration of model parameters to meet the epidemiological benchmarks. Their proposed
natural history model is limited as it includes only early adenomas, advanced adenomas,
cancer, and direct cancer. A greedy search algorithm is used to calibrate this model. They
have shown that CRC incidence and mortality rates are reduced most efficiently by
colonoscopy between ages 56 and 59 while colonoscopy at 59 is the most cost-effective
screening policy.
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There are a few studies evaluating CRC screening policies with a combination of
CRC screening tests (Byers et al. 1997; Eisen et al. 2000; Lieberman et al. 2001; Rex et
al. 2000; Winawer et al. 1997). Telford et al. (2010) developed a probabilistic Markov
model to estimate the cost-effectiveness of CRC screening policies and to derive the
optimal screening policy among all available policies. Low-risk polyp and advanced
adenoma are the two pre-cancer states in their proposed model. The proposed model
includes localized cancer, regional cancer, and distant cancer which are also divided into
clinical and preclinical cancers. The model does not include possible adenomatous
polyps’ regression. No calibration process is described as being used in this study. Ten
different screening policies are examined using the data from the literature. They
concluded that all of the ten screening policies are cost-effective. Colonoscopy every 10
years between 50 and 75 is introduced as the most effective policy as a result of
significant reduction in CRC incidence and mortality rates. However, annual FIT
between 50 and 75 is determined as the most cost-effective policy. Frazier (2000)
developed a model similar to Telford et al.'s (2010) model to assess the cost-effectiveness
of CRC screening policies in average-risk patients. Pre-cancerous adenomas are divided
into two levels based on their risk of becoming cancer, low-risk adenoma, and high-risk
adenoma, and the model is calibrated based on logistic regression methods. Distal and
proximal parts of the colon are considered separately in this model in order to evaluate
the performance of the FS more accurately. Follow-up colonoscopy is modeled as well
for the patient diagnosed with high-risk polyps and positive FS. The comparison is done
based on ICER, discounted lifetime costs and life expectancy. Annual FOBT from age 50
to 85 in conjunction with FS every 5 years is shown to be the most cost-effective policy
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in this study. Sharaf and Ladabaum (2013) used a similar Markov model to explore the
comparative effectiveness and cost-effectiveness of colonoscopy against FS and other
CRC screening tests. The natural history model categorizes adenomas into small and
large adenomas. The model is calibrated and related outputs are validated against several
trials and studies such as the Minnesota Colon Cancer Control Study and UK Flexible
Sigmoidoscopy Trial. Calibration methods are not discussed in the published article.
Symptomatic cancer is included in this model; however, the study lacks modeling
adenoma regression possibility. Results show higher adherence on FIT tests and
colonoscopy is shown to be cost-effective versus FS. They concluded that the costeffectiveness of colonoscopy versus FS and FIT is dependent on the adherence rate
associated with colonoscopy. Dinh et al. (2013) developed a simulation model to evaluate
the cost-effectiveness of multi-modal CRC screening scenarios. The developed model,
called Archimedes, is a large-scale simulation of human physiology, diseases,
interventions, and health care systems. The model has separated the natural history into
three major steps: adenoma development, tumor growth, and cancer symptoms. The CRC
sub-model of the Archimedes was developed in collaboration with the ACS using
published epidemiological studies and clinical trials data. The sub model is calibrated
against several reports including the SEER report although authors have not discussed
their calibration method in the published article. Annual or biennial FIT between 50 and
65 with one time colonoscopy at 66 shown to be cost-effective and comparable with costeffective uni-modal policies with favorable impact on resources demands.
The studies listed above fall short in the level of the details they incorporate in
modeling adenomatous polyps (pre-cancerous states) due to lack of available data.
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Moreover, some of the available models (Lee and Park 2016; Van Rossum et al. 2011)
have not simulated multiple adenomatous polyps growths. Natural history model
validation is another restriction for different studies (Pil et al. 2016; Telford et al. 2010;
Van Rossum et al. 2011; Vijan et al. 2001).

Table 2-1: Specifications of the similar studies published in the literature.
Study

Model

Hybrid
scenarios

Age range
for
screening

Calibration
method.

Adenoma stages

Cancer stages

Adenoma
regression

Symptomatic
cancer

Source CRC natural history
relate data

Best result/final
conclusion

Telford et al.
2010

Markov

Yes

50-75

N/A

Low risk polyp
Advanced
adenoma

Localized, regional,
distant (Preclinical
and clinical)

No

No

Literature
SEER

50-75 Colonoscopy
every 10 years

Frazier 2000

Markov

Yes

50+

Logistic
regression
analysis.

Low risk polyp
High risk polyp

Localized, regional,
distant

No

Yes

Sharaf and
Ladabaum
2013

Markov

Yes

50-80

Methods is not
discussed

Localized, regional,
distant

No

Yes

Dinh et al.
2013

Archimedes

Yes

50-75

Methods is not
discussed

Benign polyp
Adenomatous
polyp

Cancer lesion

No

Yes

Li et al. 2014

Markov

No

50-80

Methods is not
discussed

Small,
medium, large

No

Yes

Vijan et al.
2007

Markov

No

50-80

N/A

Low risk polyp
High risk polyp

No

No

Small Polyp
Large Polyp

Pil et al. 2016

Markov

No

50+

N/A

Low-risk polyp
High-risk polyp

Van Rossum
et al. 2011

Markov

No

50-75

N/A

Advanced
adenoma

Lee and Park
2016

Markov

No

50-80

Not mentioned
N/A

Polyp

Prakash et al.
2017

CMOST

No

NA

Greedy search
algorithm

Early adenoma
Advanced
adenoma

Localized, regional,
distant (Preclinical
and clinical)
Localized, regional,
distant (Preclinical
and clinical)
TNM CRC stage
classification

TNM CRC stage
classification
Early cancer
Cancer
Advanced cancer
Cancer, direct
cancer
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Literature
SEER
Literature
SEER
MEDLINE
MEDLINE, Cochrane Database
of Systematic Reviews, Web of
Science, PubMed
Clinical data
Literature
Literature
SEER

50-85 Annual FOBT,
FS every 5 years
Cost-effectiveness is
depended on the
adherence rate
50-65 Annual or
biennial FIT,
colonoscopy at 66
Colonoscopy interval
affects costeffectiveness
50-80 colonoscopy
every 10 years
Policies are 100 %
cost-effective for
males and 97% for
women
One time FIT between
50 and 75

No

No

Clinical data
Literature

No

Yes

Clinical data

No

Yes

Literature

50-80 Annual FOBT

Yes

Yes

Literature
SEER
MEDLINE

One time colonoscopy
between 56 and 59

CHAPTER 3
METHODOLOGY
In this section, the proposed natural history and simulation model modules are
presented. A detailed Markov framework is developed to model CRC dynamics. The
details of the proposed Markov model are presented in Section 3.1. Simulation models
characterizing CRC dynamics and possible preventive interventions through CRC
screening tests are presented in Sections 3.2 and 3.3, respectively. The detail of the
calibration process for estimating the age-specific and size-specific transition
probabilities of the Markov model is provided in Section 3.4.
3.1

CRC Natural History Model

A Markov chain framework is used to model the CRC natural history. The
proposed Markov framework is shown in Figure 3-1. The state space of the proposed
Markov model is

, where state 0 represents no adenoma. Similar to

MISCAN-Colon model (Loeve 2000), states 1 through 3 represent a diminutive adenoma
(

), a medium adenoma (

) and a large adenoma (

),

respectively. States 4 through 6 represents localized, regional, and distant stage cancers,
respectively. The localized stage represents the stage where the cancer tissue is still
confined to the primary site. The regional stage represents the stage at which cancer has
spread to regional lymph nodes. The last stage is the distant stage where the cancer tissue
has metastasized to the other parts. Based on the TNM classification of malignant tumors
17
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system, we assume that localized, regional and distant stages refer to stage I, both stage II
and III, and stage IV, respectively (National Cancer Institute). The transition probability
from state to state for age group is denoted by

. The transition periods are

assumed to be one year. Based on a previous study (Rex et al. 1997), and as reflected in
the Markov model, an adenomatous polyp can grow or regress spontaneously. However,
once an adenomatous polyp grows to become cancer, the probability of cancer regression
without a treatment involvement is negligible. For simplification, we assume these rates
are zero. The probability of more than one transition from a given state in one year (e.g.,
the growth of a localized cancer from no adenoma state) is considered to be zero due to
the negligibility of these rates (Sharaf and Ladabaum 2013).

Figure 3-1: Proposed Markov model representing dynamics of adenomatous polyps.

We refer to a patient status by a vector of length six, that is
, where

,

, and

represent the number of small, medium, and large

19
adenomatous polyps, respectively, and

,

, and

represent the number of

localized cancer (LC), regional cancer (RC), and distant cancer (DC) tissues,
respectively. For instance, a patient with two small and a large adenomatous polyps and a
regional cancer tissue is represented by (2, 0, 1, 0, 1, 0). Previous studies have shown that
the probability of having more than six adenomas/cancer tissues in an individual is
negligible (Sherer et al. 2013). Therefore, we assume that the maximum number of
adenomatous polyps/cancer tissues in our model is limited to six (i.e.,
).
3.2

CRC Natural History Simulation Model

Figure 3-2 presents a one-year dynamics of the proposed CRC natural history
simulation model. Simulation of each patient starts at birth (age zero) and the patient is
followed until he is terminated from the model either due to CRC related death or a
competing cause of death. Age 100 is considered the simulation terminating age,
consistent with the maximum life expectancy in the U.S. life table (Arias et al. 2017).
Note that the maximum number of adenomatous polyps is assumed to be six. Each
individual adenomatous polyp and cancer tissue dynamics (incidence, progression, and
regression) are simulated according to the natural history model presented in Figure 3-1.
At the beginning of each year, the possibility of adding adenomatous polyp(s) is
evaluated based on adenomatous polyps’ incidence rates and the number of existing
adenomatous polyps. Existing adenomas may progress or regress during the year as
captured by the natural history model. We assume that the patient status (number and
type of adenomas/ cancerous tissues) is updated at the beginning of each year and
remains the same during the year.
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Figure 3-2: CRC natural history simulation framework

3.3

Screening Module Simulation

Figure 3-3 and Figure 3-4 show the screening and cancer detection simulation
modules for stool-based and visual CRC screening tests, respectively. As discussed in
Section 3.1, at the beginning of each year the patient status is updated using the natural
history model. If a screening test is prescribed in a year, the patient undergoes the
screening test (perfect adherence to the prescribed test). During each year, if CRC is
present in the patient's body, it may either become symptomatic or be detected through
screening tests. We assume that any positive result from a stool-based test is followed up
by a colonoscopy (Figure 3-4) and a biopsy test is performed after receiving a positive
result on an endoscopic-based test (Figure 3-3). A biopsy may be performed during a
colonoscopy or any other endoscopic procedures where a gastroenterologist is able to
retrieve a sample from colon or rectum (Cancer Treatment Centers of America 2015).
Due to the high sensitivity of biopsy test for cancer in this study, we assume that biopsy
is a perfect test and reveals the true health status of the patient (Petrelli et al. 1999). It is
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assumed that there is a disutility associated with each test depending on the
aggressiveness of the test. Patients may receive false positive or false negative results
depending on the sensitivity and specificity of the prescribed screening test. We assume
that there is a disutility associated with receiving a false positive result. If not detected
through screening, the cancer may develop symptoms. Symptomatic cancers are modeled
using CRC mean sojourn time concept. Cancer sojourn time is defined as the time
between the onset of preclinical cancer and the point at which cancer becomes
symptomatic (Zheng and Rutter 2012). Cancer sojourn times are randomly generated
according to the available distributions at the time of cancer onset. If a CRC case remains
undetected, either due to false negative results or as a result of no scheduled screening
test in the period between the cancer onset and the time that the cancer becomes
symptomatic, cancer will show symptoms at the simulated scheduled time. The proposed
simulation model does not incorporate the post-diagnosis procedures (cancer treatment
and surveillance). Instead, we assume that upon cancer detection, the remaining stagespecific life expectancy and expected treatment and surveillance costs are accumulated
and the patient's simulation is terminated.
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Figure 3-3: Endoscopic-based CRC screening module of the simulation model.

Figure 3-4: Stool-based CRC screening module of the simulation model.

3.4

Model Calibration Process

The dynamics of adenomatous polyps (colonic polyps in general) is not wellstudied. In this study, we calibrate the parameters of the proposed simulation model
(representing a detailed dynamics of pre-cancerous (adenomatous polyps) and post
cancerous states) using age-specific CRC incidence rates and CRC stage distribution
reported by the SEER as output measures. The proposed model transition rates are age-
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specific to account for the impact of age as a significant CRC risk factor. SEER report
(Howlader et al. 2016) includes the number CRC incidences per 100,000 individuals for
18 different age-groups, including 17 age-groups in 5-year increments for patients
younger than 85 and an age-group of patients older than 85.
In this study, a combination of random search and machine learning approaches
are used for the simulation model calibration. Figure 3-5 shows the proposed calibration
process. Note that the proposed model parameters are age-specific and are estimated in
five year increments. The calibration process consists of two main phases. In the first
phase, a random search method is used to find neighborhoods yielding acceptable errors
below predefined thresholds. In the second phase, machine learning classification
methods are applied to search the parameter set space to expedite the calibration process.

Figure 3-5: An overview of the calibration process.

For the first output measure, CRC age-specific incidence rates, the weighted sum
of relative errors of the estimated measures is used to evaluate the goodness of fit of an
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estimation. Let
age-group

and

represent the observed and estimated CRC incidence rates of
, respectively. The goodness of fit value for the first output

measure is
Eq. 3-1

where

is the weight associated with the

age group. The necessity of using weights

is discussed in Section 3.4.1.
For the second output measure, CRC stage distribution, the minimum of the sum
of absolute errors (SAE) as presented in Eq. 3-2 is used to select best parameter sets.
Eq. 3-2

where

denotes different CRC stages, and

observed and estimated ratio of CRC cases in stage
3.4.1

and

represent the

, respectively.

Characterization of the Training Data
In the calibration process, the training data includes sets of Markov model

transition probabilities (to be estimated) as inputs and a set of classes each representing a
level of deviation from the SEER reported measures as the output. As the two output
measures (incidence rates and CRC stage distribution) are continuous variables, we
discretized (labeled) the outputs into different classes in order to apply classification
machine learning methods. The discretization process occurs through defining envelopes
and scores for the continued outputs based on the deviation from the observed measures
reported by the SEER. An envelope is an interval or a set of two intervals defined around
an observed output measure and represents a level of deviation from the observed
measure. Let

denote the

envelope defined around the observed
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incidence rate for age-group , and

denote a predefined threshold controlling

the tolerance of deviation from the observed incidence rate in the
(

) envelope models an infinite error theoretically. Let

envelope. The last

be the score assigned to the

envelope representing how close the estimated rates are from the observed rates.
Table 3-1 represents a SEER incidence rate, hypothetical envelopes surrounding the rate,
and the associated scores.
Table 3-1: Schematic envelopes formed around an incidence rate and their associated scores.
Tolerance

Envelope

Score

…

…

…

…

…

…

-

Let
(

denote the final score associated with the estimated incidence rates

) obtained from the simulation model. The final score of a parameter set is

calculated as the weighted sum (over all the age-groups) of scores of the envelopes which
include the estimated incidence rates. Eq. 3-3 calculates the final score of a parameter set
based on the estimated incidence rates. Note that a larger score implies a larger error and
the goal is to minimize the overall score. Therefore, lower scores must be assigned to the
envelopes with smaller tolerance.
Eq. 3-3
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is the Kronecker delta function and is defined in Eq. 3-4,

where

associated with the

envelope, and

the score

is the weight associated with age-group

.
Eq. 3-4

The length of an envelope is calculated based on the magnitude of the associated
incidence rates of the corresponding age-group. At younger ages, when the incidence
rates are lower, the envelopes are smaller. As the patients become older, the envelope
sizes increase. Therefore, the

envelopes at a younger age-group represents a smaller

error compared to the counterpart envelope

at older age-group. To account for the

different error representation of envelopes at different age-groups, envelope scores are
weighted to enforce more weights on the age-groups with wider envelopes.
Similarly, envelopes are developed around the observed CRC stage ratios
with a predefined tolerance
denote the

, specifying the envelope's size. Let

envelope defined around the actual rate

The final score associated with the estimated ratios, (

.
) obtained from the

simulation model, is calculated as the summation of the scores of the envelopes which
include the estimated cancer stage ratio, as presented in Eq. 3-5.
Eq. 3-5

where
value 1 if

is the Kronecker delta function and is defined similar to Eq. 3-4 and it takes
, and 0, otherwise.

27
The final class that a set of parameters belongs to is determined based on the
maximum value of
between

and

and

, i.e.,

. Let

parameter sets for which

. Note that
, denote the
, where

class. Class

is always
is defined as

is the score assigned to the

envelopes. Using the above process, the simulation data is transformed into labeled data.
A balanced training data set is desirable in machine learning in order to increase
the accuracy and precision of machine learning methods (Batista et al. 2004). Balance of
a training data set is a function of tolerances and envelope scores since the final score of a
parameter set is calculated based on the envelope scores of the age-groups. For example,
given that we have four envelopes, desired tolerances and scores divide the training data
into three different classes with each class containing approximately 33% of the data.
3.4.2

Decision Tree Model
A Decision Tree (DT) is an inductive learning algorithm consisting of several

recursive decision rules, arranged hierarchically similar to the structure of a tree (Pradhan
2013). The algorithm is based on the “divide and conquer” strategy and generates a
classification tree using the training data/samples. The tree includes internal nodes (
and

in Figure 3-6) and external (

in Figure 3-6) nodes. At each internal node,

a test is applied to one or more attribute values to decide which node to visit next. An
external node, also known as a terminal node, characterizes the output class. DT are
recommended to extract unknown patterns from large data-sets with distinction purposes.

28

Figure 3-6: A schematic decision tree.

In order to train the DT, a training data set is first generated using the simulation
model. Generated data are labeled using the approach described in Section 3.4.1. The DT
is then trained and validated using the labeled data set. If the trained DT does not meet
the acceptable level of accuracy, a new set of envelopes and scores will be generated.
This process is iterated until an acceptable level of accuracy is reached. After the DT is
trained, random parameter sets are generated to be classified by the trained DT. Note that
a random parameter set is a set of transition probabilities (without the output measures).
The DT classifies (labels) the randomly generated parameter sets into different classes.
Parameter sets that are classified into the best class (with

) are then fed

into the simulation model to be evaluated. Among the parameter sets examined by the
simulation model, the one which gives the smallest errors, calculated using Eq. 3-1 and
Eq. 3-2, is selected. If the errors associated with the best data set are less than the
acceptable thresholds (

and

respectively), the calibration process is completed.

Otherwise, new parameter sets are randomly generated and the process is repeated until
an acceptable error level is reached.
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In summary, the proposed calibration method expedites the calibration process by
exploiting machine learning tools. Specifically, instead of searching the transition
probability space through time-consuming simulation model, the DT identifies the
neighborhoods that are more likely to have the "optimal" parameter sets at a significantly
faster pace. The simulation is then run only on the parameter sets identified as good
solutions by the DT. For example, for 1000 parameter sets, the simulation model
(simulating 100,000 patients per parameter set) takes over 140 hours. The DT, however,
classifies the same number of parameter sets in less than a minute.

CHAPTER 4
MODEL PARAMETER ESTIMATION
The main challenge in the parameter estimation of the proposed model is to
estimate the Markov model age-specific transition probability matrices. Particularly, the
proposed model is very complex since it incorporates low level details of adenomas
dynamics, including regression probabilities. An active learning approach, as discussed in
Section 3.4, is used to estimate these parameters. Section 4.1 provides the details of the
calibration process results for estimation of age-specific transition probabilities. Please
note that the model is calibrated to represent the U.S. male population. Section 4.2
presents the data sources used for estimation of the remaining parameters.
4.1

Calibration Results

Using the normalization constraint in the proposed Markov model, the number of
the transition probabilities to be estimated for a given age-group is decreased from 15 to
9. Therefore, given that there are 18 age-groups, the total number of transition
probabilities to be estimated is 162.
Using the random search method, at the end of the first phase of the calibration
process the minimum error achieved for each output measure is 8%. In the second phase,
three thousand random parameter sets in the neighborhoods of the estimated parameters
(obtained in the first phase of the calibration process) are generated. The generated
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parameter sets are then fed into the simulation model to calculate the output measures of
interest. The result of the simulation model is then used to specify the characteristics of
the discretization process which includes specifying envelopes and scores and to train the
classification tool. Note that too many envelopes, and therefore classes, make the model
more complicated and thereby slower. Moreover, note that we are only interested in the
class with the smallest error. Therefore, there is no need to make the model more
complicated by defining too many envelopes. There is no specific rule on what the
numbers of envelopes, tolerance values and score must be. Therefore, using a trial and
error approach, different combinations are examined for the model tuning. The results
implied that setting the number of envelopes to three does not reach the desired accuracy
and the model does not clearly differentiate the classes. Table 4-1 presents the best
parameter values found in the calibration process. The score associated with the fourth
envelope is considerably larger than that of the other envelopes to ensure that parameters
sets with high deviation from the actual output measures in one or more age groups are
not classified in the first class (with the lowest overall score).
The classifiers are then trained using 80% of the training data set and validated
using the remaining 20% of the data. Three different machine learning methods, namely
Multilayer Perceptron (MLP), Naive Bayes (NB) and Decision Tree (DT) are tested. DT
model outperformed the other two models in terms of accuracy and precision. We use the
Gini Index to evaluate splits in the data set when training the DT. The DT reached an
accuracy of 91%.
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Table 4-1: List of the tolerances and scores obtained in the model tunning process.
Incidence rate tolerance

Stage distribution tolerance

Score

0.1

0.05

0

0.2

0.1

3

0.4

0.2

6

>0.4

>0.2

200

After the DT is trained and validated, new parameter sets are randomly generated
and classified using the trained model. The parameter sets that are classified in the first
class with the lowest score then are fed into the simulation model for exact error
evaluation. Acceptable error threshold for CRC incidence rates ( ) and CRC stage
distribution ( ) are set to 5% and 1%, respectively. The error threshold for the CRC
incidence rate is selected to be higher since this error measures the deviation from the
observed incidence under 18 different age-groups and therefore even a reasonable error in
each age-group may add up to a big error. The minimum error for the first output
measure (incidence rate) and second output measure (CRC stage distribution) achieved
are 3.1% and 0.46%, respectively. Figure 4-1 and Figure 4-2 show the estimated
incidence rates and CRC stage distribution, respectively, plotted against the same
measures reported by the SEER. The estimated age-specific transition probabilities are
presented in Table A-1 and Table A-2 in APPENDIX A.
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Figure 4-1: Age specific estimated incidence rates using DT (red) and incidence rates
reported by SEER (blue).

Figure 4-2: CRC stage distribution obtained by the calibration model compared with those
reported by SEER.
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4.2

Other Parameters

Table A-6 presents the data sources used for parameter estimations. Natural cause
and CRC related mortality rates are calculated using SEER cancer statistics review
(Howlader et al. 2016) and the US life table (Arias et al. 2017). Age and stage specific
life expectancy of CRC patients are estimated using the MD Anderson CRC survival
calculator (MD Anderson Cancer Center CRC Survival Calculator 2009). Screening
specifications are adopted from recently published literature (Erenay et al. 2014; Knudsen
et al. 2016). Screening costs are the source of most of the disparities in cost-effectiveness
studies. In order to retrieve the most accurate cost estimates, we adopted the screening
and treatment costs from most recent published studies to make sure there are no
significant technology changes. In addition, all costs are adjusted to the calendar year
2018 dollars by using the Bureau of Labor Statistics Consumer Price Index (Bureau of
Labor Statistics 2018). The CRC sojourn time is assumed to follow an exponential
distribution (Loeve 2000) and the mean parameters are adopted from Brenner et al.'s
(2011) study.
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Table 4-2: Data source and estimated parameters used in the simulation model.
Parameter
Age-specific precancerous transition
probabilities
Age-specific post-cancerous transition
probabilities
Age-specific mortality rates
CRC localized stage mortality rates
CRC regional stage mortality rates
CRC distant stage mortality rates
Age-specific quality adjusted life year
<= 44
45-54
55-64
65-74
75+
Colonoscopy disutility
FS disutility
FIT disutility
FOBT disutility

Value

Reference

Table A-1

Sherer et al. 2013

Table A-2

Macafee et al. 2008

US. Life Table
0.0542
0.1677
0.6469

Arias et al. 2017

0.91 year
0.78 year
0.77 year
0.75 year
0.73 year
11 days
2 days
1 days
1 days

Stage-specific CRC life expectancy

Table A-3

CRC mean sojourn time
Screening tests sensitivities
Colonoscopy specificity
FS specificity
FIT specificity
FOBT specificity
Colonoscopy cost
FS cost
FIT cost
FOBT cost
Treatment costs

Table A-4
Table A-5
86%
87%
89.8%
92.5%
$1192.6
$548.47
$24.88
$24.88
Table A-6

Macafee et al. 2008

Fryback and Lawrence 1997

Erenay et al. 2014
Mayo clinic 2018
American Cancer Society 2018
American Cancer Society 2018
MD Anderson Cancer Center CRC
Survival Calculator 2009
Brenner et al. 2011
Knudsen et al. 2016
Knudsen et al. 2016

Prakash et al. 2017
Sharaf and Ladabaum 2013
Bureau of Labor Statistics 2018
Joseph 2018

CHAPTER 5
NUMERICAL RESULTS
Different screening policies are implemented to a cohort of one hundred thousand
males. Screenings are applied to the cohort of individuals aged from 50 to 75. The
screening policies differ in the type of screening tests and screening intervals. A costeffectiveness analysis on a broad set of uni-modal and multi-modal CRC screening
policies is performed. Specifically, we assess 78 different policies including noscreening, five CRC screening policies recommended by different US health agencies,
and 72 alternative multi-modal screening policies. The five in-practice screening policies
analyzed are Colonoscopy at 50, 60 and 70, annual FIT, annual FOBT, FS every 5 years
and FOBT every 3 years in conjunction with FS every 5 years. FIT, FOBT, colonoscopy,
and FS are the screening modalities considered in the alternative screening policies.
Policies are generated by combining policies recommended by the health agencies and
some recent studies. In the evaluated multi-modal policies, patients undergo two different
types of tests: a stool-based test and a visual test. Stool-based tests are associated with
lower cost and are less aggressive compared to visual tests. Visual tests, on the other
hand, are more sensitive and costly. We assume each year at most one screening test is
performed on a patient unless the patient receives a positive result and is referred for a
biopsy. In a year with a confluence of two different screening tests, only the visual test
(FS or colonoscopy) is used. The frequencies of the tests are selected based on the
36
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recommended frequencies by the health agencies and the literature. Stool-based tests are
prescribed annually or biennially, and FS and colonoscopy are prescribed at 5-year and
10-year frequencies, respectively. The policies investigated in this study are listed in
Table 5-1.
All 78 policies considered in this study are represented in Figure 5-1. The blue
points are the “inefficient” or "dominated" policies, or the policies that are each
dominated by other screening policy(ies) with a higher QALYs and lower cost. The
identified “efficient" or "dominant" and in-practice policies are presented in green and
red, respectively. FOBT biennially in conjunction with one time Colonoscopy at 60,
FOBT biennially along with one time Colonoscopy at 50, FIT biennially in conjunction
with two times FS at 60 and 65, FIT biennially with one time Colonoscopy at 65,
Colonoscopy at 50, 60 and 70, FOBT biennially along with two times Colonoscopy at 55
and 65, FOBT annually with 2 times FS at 70 and 75, FOBT annually in conjunction
with FS at 50,55 and FIT biennially along with FS every 5 years are the nine identified
dominant policies. The structure of the identified dominant policies show that undergoing
endoscopic-based tests between age 55 and 65 benefits the patients. In addition,
prescribing stool-based tests for the patients biennially is shown to be more cost-effective
as suggested by 6 of the identified dominant policies. Prescribing stool-based tests
annually seems to unnecessarily increase the expected cost while it does not significantly
affect the expected QALYs. As the results show, for each in-practice policy, there is an
alternative policy that results in higher QALYs with the same or a lower cost of the inpractice policy. For instance, consider the in-practice policy of FS every 5 years. This
policy yields the highest expected QALYs (67.05 years), with an associated expected cost
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of $3,762, among the in-practice polices. However, the alternative policy of FOBT
annually, in conjunction with FS at 70 and 75 yields both higher expected QALYs (67.06
years) and lower expected cost ($3,684). The results show all the 77 policies evaluated in
this study benefit the patients through increased QALYs and decreased CRC mortality
compared to no screening policy. In most cases, combining stool-based tests with visual
tests will benefit patients with higher life expectancy and lower expected cost. Multimodal policies are associated with higher reduction rates in CRC incidence and mortality
compared with uni-modal scenarios.

Figure 5-1: Efficient frontier versus the in-practice policies.

In order to evaluate the performance of different CRC screening policies,
incremental cost-effectiveness ratio (ICER) is calculated. ICER is calculated as the
expected cost difference per expected QALYs difference for every 2 consecutive policies
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while all screening policies are sorted in expected QALYs in an increasing order. Let
and

denote two consecutive policies with associated

respectively and
policies
policy
value for

and

and

,

. Eq. 5-1 calculates the ICER value when comparing
and represents the ratio of the additional cost that must be paid under

for one additional unit of QALYs when compared with policy
represents that policy

is dominated by policy

. A negative

since policy

is

associated with higher expected cost and lower expected QALYs. ICER for dominant
screening policies is calculated as the cost difference per QALY gained relative to the
nearest efficient frontier policy (Dinh et al. 2013).
Eq. 5-1
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Table 5-1: Cost, QALYs, and ICER associated with the investigated policies.
Policy

QALYs

Cost

ICER

No screening

66.61

$1,306

NA

FIT annually,
Colonoscopy at 50,
60, 70

66.91

$6,221

FIT annually, FS at
55,60

66.91

FIT biennially,
Colonoscopy at 60, 70

Policy

QALYs

Cost

ICER

FOBT annually,
Colonoscopy at 60

66.99

$3,870

Dominated

Dominated

FOBT biennially,
Colonoscopy at 60

66.99

$2,634

$3,486

$4,342

Dominated

FOBT biennially,
Colonoscopy at 65, 75

66.99

$3,546

Dominated

66.91

$3,718

Dominated

FIT annually,
Colonoscopy at 60

67.00

$4,505

Dominated

FOBT annually,
Colonoscopy at 55,
65, 75

66.91

$5,480

Dominated

FIT biennially,
Colonoscopy at 70

67.00

$2,934

Dominated

FIT annually, FS at
70, 75

66.92

$4,273

Dominated

FIT biennially,
Colonoscopy at 50,
60, 70

67.00

$4,591

Dominated

FIT annually, FS at
60, 65

66.93

$4,328

Dominated

FOBT annually, FS at
55, 60

67.00

$3,776

Dominated

FIT biennially,
Colonoscopy at 75

66.93

$3,034

Dominated

FOBT annually,
Colonoscopy at 50

67.00

$3,886

Dominated

FOBT biennially, FS
at 55, 60

66.93

$2,748

Dominated

FOBT biennially,
Colonoscopy at 55

67.00

$2,744

Dominated

FIT annually,
Colonoscopy at 55,
65, 75

66.94

$6,129

Dominated

FOBT every 3 years ,
FS every 5 years

67.01

$3,245

Dominated

FIT biennially,
Colonoscopy at 60

66.94

$2,941

Dominated

FOBT annually, FS at
60, 65

67.01

$3,735

Dominated

FOBT annually,
Colonoscopy at 60, 70

66.94

$4,666

Dominated

FOBT annually, FS
every 5 years

67.01

$5,101

Dominated

FOBT annually,
Colonoscopy at 65, 75

66.94

$4,559

Dominated

FOBT annually,
Colonoscopy at 75

67.01

$3,755

Dominated

FOBT annually,
Colonoscopy at 50,
60, 70

66.94

$5,582

Dominated

FIT annually

67.02

$3,680

Dominated

FIT annually,
Colonoscopy at 55, 65

66.95

$5,391

Dominated

FIT annually,
Colonoscopy at 65

67.02

$4,479

Dominated

FIT annually, FS
every 5 years

66.95

$5,610

Dominated

FIT biennially,
Colonoscopy at 55

67.02

$3,085

Dominated

FIT biennially,
Colonoscopy at 55,
65, 75

66.95

$4,852

Dominated

FOBT annually,
Colonoscopy at 50, 60

67.02

$4,750

Dominated

FIT biennially, FS at
55, 60

66.95

$3,016

Dominated

FOBT biennially, FS
at 50,55

67.02

$2,781

Dominated

FIT biennially, FS at
65, 70

66.95

$2,963

Dominated

FOBT biennially, FS
every 5 years

67.02

$4,183

Dominated

FOBT biennially, FS
at 70, 75

66.95

$2,682

Dominated

FOBT biennially,
Colonoscopy at 50

67.02

$2,692

$2,031
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Policy

QALYs

Cost

ICER

FIT annually,
Colonoscopy at 75

66.96

$4,388

Dominated

FIT annually,
Colonoscopy at 60, 70

66.96

$5,304

FOBT biennially,
Colonoscopy at 70

66.96

FOBT biennially,
Colonoscopy at 75

QALYs

Cost

ICER

FOBT biennially,
Colonoscopy at 65

67.02

$2,737

$177,503

Dominated

FOBT biennially,
Colonoscopy at 60, 70

67.02

$3,424

Dominated

$2,682

Dominated

FOBT biennially,
Colonoscopy at 50,
60, 70

67.02

$4,306

Dominated

66.96

$2,724

Dominated

FIT annually,
Colonoscopy at 50

67.03

$4,502

Dominated

FIT annually, FS at
50, 55

66.97

$4,364

Dominated

FIT biennially, FS at
50, 55

67.03

$3,064

$332,458

FOBT annually,
Colonoscopy at 55

66.97

$3,855

Dominated

FIT biennially, FS at
60, 65

67.03

$2,985

$22,856

FIT annually,
Colonoscopy at 55

66.98

$4,492

Dominated

FOBT annually,
Colonoscopy at 65

67.03

$3,820

Dominated

FIT annually,
Colonoscopy at 70

66.98

$4,441

Dominated

FOBT biennially,
Colonoscopy at 55,
65, 75

67.03

$4,517

Dominated

FIT annually, FS at
65, 70

66.98

$4,312

Dominated

FOBT annually

67.04

$3,100

Dominated

FIT biennially,
Colonoscopy at 50

66.98

$2,974

Dominated

FIT biennially,
Colonoscopy at 65

67.04

$3,070

$834

FIT biennially,
Colonoscopy at 50, 60

66.98

$3,803

Dominated

FIT biennially,
Colonoscopy at 55, 65

67.04

$4,023

Dominated

FIT biennially,
Colonoscopy at 65, 75

66.98

$3,883

Dominated

FOBT annually,
Colonoscopy at 70

67.04

$3,804

Dominated

FOBT annually, FS at
65, 70

66.98

$3,726

Dominated

FOBT biennially,
Colonoscopy at 50, 60

67.04

$3,528

Dominated

FOBT annually,
Colonoscopy at 55, 65

66.98

$4,714

Dominated

Colonoscopy at 50,
60, 70

67.05

$3,341

$44,760

FOBT biennially, FS
at 60, 65

66.98

$2,747

Dominated

FS every 5 years

67.05

$3,762

Dominated

FOBT biennially, FS
at 65, 70

66.98

$2,718

Dominated

FOBT annually, FS at
70, 75

67.06

$3,684

$4,387

FIT annually,
Colonoscopy at 50, 60

66.99

$5,397

Dominated

FOBT biennially,
Colonoscopy at 55, 65

67.06

$3,682

$22,824

FIT annually,
Colonoscopy at 65, 75

66.99

$5,226

Dominated

FOBT annually, FS at
50, 55

67.08

$3,781

$6,859

FIT biennially, FS at
70, 75

66.99

$2,947

FIT biennially, FS
every 5 years

67.09

$4,442

$43,183

Dominated

Policy
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Table 5-1 presents all the policies investigated in this study with their associated
QALYs, cost and ICER. Willingness to pay (WTP) is defined as the maximum price at or
below which the patient (consumer) will buy a service (product) (Miller et al. 2011). At
$50,000 WTP threshold (Sharaf and Ladabaum 2013), among the 11 dominant policies, 9
policies are cost-effective out of which 8 policies are multi-modal. Multi-modal policies
are also associated with lower ICER compared with the identified cost-effective unimodal policy (Colonoscopy at 50, 60 and 70).
The performance of the in-practice policies and best alternative policies in terms
of expected QALYs, incidence reduction, and mortality reduction, when compared with
no screening policy are compared in Table 5-2. Among the in-practice policies
colonoscopy at 50, 60 and 70 outperforms other policies in terms of expected QALYs
(67.05), incidence and mortality reduction (86.5% and 89.4% respectively). Comparing
this policy with the alternative policies, FIT biennially in conjunction with FS every 5
years benefits the patients with higher expected QALYs (67.09). FOBT biennially along
with three times colonoscopy at 50, 60 and 70 serves the patients with higher incidence
reduction (88.6%) and FIT annually, colonoscopy at 55, 65 and 75 benefits patients with
higher mortality reduction (93%) compared to the best identified in-practice policy.
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Table 5-2: In-practice policies and best identified alternative policies in terms of the expected
QALYs, incidence reduction, and mortality reduction - number in parentheses represent
confidence intervals (CI).
Expected
QALYs

Incidence
Reduction

Mortality
Reduction

No screening

66.61
(66.59,66.63)

-

-

FIT annually

67.02
(67.00,67.04)

69.8%

85.4%

FOBT annually

67.04
(67.01,67.07)

60.4%

80.1%

FS every 5 years

67.05
(67.03,67.07)

71.1%

81.1%

FOBT every 3 years, FS every 5 years

67.01
(66.99,67.03)

62.7%

79.0%

Colonoscopy at 50, 60 and 70

67.05
(67.02,67.07)

86.5%

89.4%

FIT biennially, FS every 5 years

67.09
(67.07,67.11)

75.8%

87.1%

FOBT biennially, Colonoscopy at 50, 60,
70

67.02
(67.00,67.04)

88.6%

91.9%

FIT annually, Colonoscopy at 55, 65, 75

66.94
(66.91,66.97)

87.1%

93.0%

Alternative

In-practice

Policy

CHAPTER 6
CONCLUSION
As implied by multiple health agencies, currently there is no consensus on which
CRC screening policy is the most effective. In this study, we adopted a Markov chain
framework to model CRC natural history. We used Monte Carlo simulation approach to
model the CRC dynamics and quantify the effectiveness of CRC preventive
interventions. Using active learning, specifically a decision tree, we devised an
innovative calibration process to estimate the parameters of the detailed proposed natural
history model, i.e., age-specific and size-specific adenoma progression and regression
rates as well as age-specific CRC progression rates. This method calibrates the proposed
simulation model through a more efficient and faster process compared to other methods
used in the literature such as trial and error, random sampling, and grid search.
A cohort of 100,000 males is simulated under 78 different CRC screening policies
using the calibrated model. A cost-effectiveness analysis is performed on different
screening policies. Screening policies are compared in terms of the associated expected
screening and treatment cost, expected QALYs, and reduction in the CRC incidence and
mortality rates. The numerical analysis results show that in most cases, combining stoolbased tests with visual tests will benefit patients with higher life expectancy and lower
expected cost. Multi-modal policies are associated with higher reduction rates in CRC
incidence and mortality compared with uni-modal scenarios. Among the nine identified
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dominant policies under $50,000 WTP threshold, eight policies are multi-modal. Multimodal policies are also associated with lower ICER compared with the identified costeffective uni-modal policy.
This study has several limitations. First, using multiple data sources for parameter
estimation introduces some potential sources of errors. Screening and treatment costs are
usually difficult to estimate due to the wide estimation variation in the literature. Second,
a discretization approach is taken in this study when calibrating the model through the
DT training as DT is a classification approach. The discretization introduces some errors
due to classifying different errors in one class. Employing prediction models that can
work with continuous variables, and thereby avoiding discretization, would result in
eliminating this error in the calibration process. This study is limited to male population
and incorporates age as the only CRC risk factor. However, other risk factors such as
gender and family history, etc., need to be taken into account for more precise disease
modeling. A risk stratification model which takes into account patient-specific risk
factors and recommend policies accordingly would be a possible future direction.

APPENDIX A
MODEL PARAMETERS USED IN THE SIMULATION MODEL
Table A-1: Age-specific pre-cancer transition probabilities
Age group
1-4

0.992

0.008

0.008

0.966

0.026

0.013

0.960

0.026

0.005

0.975

0.020

5-9

0.999

0.001

0.004

0.991

0.004

0.008

0.988

0.005

0.003

0.994

0.003

10-14

0.996

0.004

0.005

0.983

0.012

0.008

0.979

0.013

0.003

0.988

0.010

15-19

0.996

0.004

0.003

0.985

0.012

0.006

0.982

0.012

0.002

0.989

0.009

20-24

0.996

0.004

0.004

0.982

0.014

0.007

0.979

0.015

0.002

0.987

0.011

25-29

0.996

0.004

0.004

0.982

0.014

0.007

0.978

0.015

0.003

0.986

0.011

30-34

0.993

0.007

0.005

0.972

0.023

0.008

0.968

0.024

0.003

0.979

0.018

35-39

0.990

0.010

0.006

0.960

0.034

0.010

0.955

0.035

0.004

0.970

0.026

40-44

0.994

0.006

0.006

0.975

0.019

0.011

0.970

0.019

0.004

0.982

0.014

45-49

0.989

0.011

0.009

0.953

0.038

0.016

0.946

0.038

0.006

0.965

0.029

50-54

0.990

0.010

0.011

0.957

0.032

0.018

0.949

0.033

0.007

0.969

0.025

55-59

0.990

0.010

0.009

0.958

0.032

0.016

0.951

0.033

0.006

0.969

0.025

60-64

0.989

0.011

0.009

0.955

0.035

0.016

0.948

0.036

0.006

0.967

0.027

65-69

0.987

0.013

0.012

0.944

0.044

0.020

0.934

0.045

0.008

0.958

0.034

70-74

0.988

0.012

0.010

0.951

0.039

0.018

0.943

0.040

0.007

0.964

0.030

75-79

0.988

0.012

0.011

0.948

0.041

0.018

0.940

0.042

0.007

0.961

0.032

80-84

0.988

0.012

0.011

0.948

0.041

0.019

0.939

0.042

0.007

0.962

0.031

85+

0.990

0.010

0.010

0.957

0.033

0.017

0.950

0.034

0.006

0.968

0.025
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Table A-2: Age-specific cancer states transiotion probabilities.
Age group
1-4

0.710

0.290

0.581

0.419

5-9

0.709

0.291

0.580

0.420

10-14

0.701

0.299

0.580

0.420

15-19

0.695

0.305

0.576

0.424

20-24

0.694

0.306

0.576

0.424

25-29

0.694

0.306

0.576

0.424

30-34

0.692

0.308

0.571

0.429

35-39

0.687

0.313

0.568

0.432

40-44

0.686

0.314

0.568

0.432

45-49

0.686

0.314

0.563

0.437

50-54

0.686

0.314

0.545

0.455

55-59

0.686

0.314

0.553

0.447

60-64

0.684

0.316

0.549

0.451

65-69

0.685

0.315

0.548

0.452

70-74

0.685

0.315

0.547

0.453

75-79

0.674

0.326

0.541

0.459

80-84

0.674

0.326

0.539

0.461

85+

0.670

0.330

0.539

0.461
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Table A-3: Stage-specific life expectancy of CRC patients.
Age
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Localized
64.76
63.95
63.10
62.31
61.49
60.66
59.85
58.99
58.08
57.12
56.32
55.51
54.66
53.87
53.06
52.23
51.42
50.56
49.66
48.69
47.91
47.12
46.28
45.49
44.69
43.87
43.06
42.21
41.31
40.34
39.57
38.78
37.94
37.16
36.36
35.54
34.74
33.89
32.99
32.02
31.26
30.48
29.66
28.90
28.11
27.30
26.51
25.66
24.77
23.81

Regional
50.41
49.81
49.19
48.62
48.00
47.34
46.70
46.02
45.23
44.30
43.62
43.02
42.41
41.83
41.21
40.55
39.91
39.24
38.45
37.52
36.85
36.26
35.66
35.09
34.48
33.82
33.19
32.52
31.73
30.80
30.14
29.55
28.95
28.38
27.77
27.12
26.49
25.82
25.03
24.10
23.45
22.88
22.29
21.73
21.13
20.49
19.87
19.20
18.42
17.49

Distant
5.32
5.25
5.23
5.23
5.21
5.21
5.19
5.17
5.12
4.52
4.51
4.46
4.44
4.43
4.42
4.42
4.40
4.38
4.33
3.73
3.72
3.66
3.64
3.64
3.62
3.62
3.60
3.58
3.54
2.94
2.93
2.88
2.86
2.85
2.83
2.83
2.81
2.79
2.75
2.28
2.15
2.14
2.10
2.07
2.06
2.05
2.05
2.03
2.01
2.00

Age
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Localized
23.06
22.35
21.63
20.89
20.18
19.44
18.67
17.86
17.01
16.06
15.42
14.80
14.17
13.54
12.88
12.23
11.54
10.78
9.96
9.02
8.56
8.12
7.65
7.19
6.71
6.20
5.63
5.01
4.26
3.36
3.25
3.11
2.80
2.62
2.42
2.17
1.81
1.61
1.29
0.83
0.82
0.78
0.72
0.66
0.63
0.56
0.56
0.52
0.48
0.27

Regional
17.00
16.49
15.96
15.41
14.87
14.38
13.79
13.16
12.43
11.52
11.03
10.62
10.17
9.76
9.30
8.87
8.38
7.80
7.11
6.21
5.95
5.67
5.36
5.08
4.75
4.44
4.07
3.62
3.02
2.18
2.12
2.02
1.98
1.91
1.84
1.75
1.63
1.44
1.06
0.69
0.65
0.58
0.58
0.51
0.47
0.45
0.40
0.36
0.34
0.31

Distant
1.97
1.66
1.52
1.40
1.36
1.10
0.73
0.71
0.65
0.63
0.60
0.58
0.56
0.55
0.54
0.54
0.52
0.51
0.50
0.50
0.47
0.36
0.34
0.28
0.26
0.25
0.25
0.24
0.23
0.22
0.21
0.19
0.13
0.13
0.08
0.06
0.06
0.05
0.04
0.04
0.04
0.04
0.03
0.02
0.02
0.01
0.01
0.01
0.01
0.01
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Table A-4: Age-specific mean sojourn time.
Age

Mean Sojourn Time (years)

1-59

5.5

60-64

5.2

65-69

4.7

70-74

4.9

75-79

5.0

80-100

5.5

Table A-5: Screening sensitivities.
Colonoscopy

FS

FOBT

FIT

Small adenoma

0.75

0.75

N/A

N/A

Medium adenoma

0.85

0.85

N/A

N/A

Large adenoma

0.95

0.95

N/A

N/A

CRC

0.95

0.95

0.70

0.74

Table A-6: CRC stage-specific treatment costs.
Stage

Initial cost (Year 1)

Surveillance Costs (Years 2-5)

Localized

$20,247

$1,305

Regional

$26,008

$2,345

Distant

$30,085

$15,057

APPENDIX B
PROGRAMMING CODE OF THE MODEL
#library(xlsx)
#list of policies
Policies<-matrix(0,100,81)
Policies[c(50:75),2]<-3
Policies[c(50,60,70),3]<-1
Policies[seq(50,75,5),4]<-4 ; Policies[seq(50,75,3),4]<-3
Policies[c(45:75),5]<-2
Policies[c(45:75),6]<-3
Policies[c(45,55,65,75),7]<-1
Policies[seq(45,75,5),8]<-4
Policies[c(50:75),9]<-2
Policies[seq(50,75,1),10]<-2 ; Policies[50,10]<-1
Policies[seq(50,75,1),11]<-2 ; Policies[55,11]<-1
Policies[seq(50,75,1),12]<-2 ; Policies[60,12]<-1
Policies[seq(50,75,1),13]<-2 ; Policies[65,13]<-1
Policies[seq(50,75,1),14]<-2 ; Policies[70,14]<-1
Policies[seq(50,75,1),15]<-2 ; Policies[75,15]<-1
Policies[seq(50,75,1),16]<-2 ; Policies[c(50,60),16]<-1
Policies[seq(50,75,1),17]<-2 ; Policies[c(55,65),17]<-1
Policies[seq(50,75,1),18]<-2 ; Policies[c(60,70),18]<-1
Policies[seq(50,75,1),19]<-2 ; Policies[c(65,75),19]<-1
Policies[seq(50,75,1),20]<-2 ; Policies[seq(50,75,10),20]<-1
Policies[seq(50,75,1),21]<-2 ; Policies[seq(55,75,10),21]<-1
Policies[seq(50,75,1),22]<-2 ; Policies[c(50,55),22]<-4
Policies[seq(50,75,1),23]<-2 ; Policies[c(55,60),23]<-4
Policies[seq(50,75,1),24]<-2 ; Policies[c(60,65),24]<-4
Policies[seq(50,75,1),25]<-2 ; Policies[c(65,70),25]<-4
Policies[seq(50,75,1),26]<-2 ; Policies[c(70,75),26]<-4
Policies[seq(50,75,1),27]<-2 ; Policies[seq(50,75,5),27]<-4
Policies[seq(50,75,2),28]<-2 ; Policies[50,28]<-1
Policies[seq(50,75,2),29]<-2 ; Policies[55,29]<-1
Policies[seq(50,75,2),30]<-2 ; Policies[60,30]<-1
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Policies[seq(50,75,2),31]<-2 ; Policies[65,31]<-1
Policies[seq(50,75,2),32]<-2 ; Policies[70,32]<-1
Policies[seq(50,75,2),33]<-2 ; Policies[75,33]<-1
Policies[seq(50,75,2),34]<-2 ; Policies[c(50,60),34]<-1
Policies[seq(50,75,2),35]<-2 ; Policies[c(55,65),35]<-1
Policies[seq(50,75,2),36]<-2 ; Policies[c(60,70),36]<-1
Policies[seq(50,75,2),37]<-2 ; Policies[c(65,75),37]<-1
Policies[seq(50,75,2),38]<-2 ; Policies[seq(50,75,10),38]<-1
Policies[seq(50,75,2),39]<-2 ; Policies[seq(55,75,10),39]<-1
Policies[seq(50,75,2),40]<-2 ; Policies[c(50,55),40]<-4
Policies[seq(50,75,2),41]<-2 ; Policies[c(55,60),41]<-4
Policies[seq(50,75,2),42]<-2 ; Policies[c(60,65),42]<-4
Policies[seq(50,75,2),43]<-2 ; Policies[c(65,70),43]<-4
Policies[seq(50,75,2),44]<-2 ; Policies[c(70,75),44]<-4
Policies[seq(50,75,2),45]<-2 ; Policies[seq(50,75,5),45]<-4
Policies[seq(50,75,1),46]<-3 ; Policies[c(50,55),46]<-4
Policies[seq(50,75,1),47]<-3 ; Policies[c(55,60),47]<-4
Policies[seq(50,75,1),48]<-3 ; Policies[c(60,65),48]<-4
Policies[seq(50,75,1),49]<-3 ; Policies[c(65,70),49]<-4
Policies[seq(50,75,1),50]<-3 ; Policies[c(70,75),50]<-4
Policies[seq(50,75,1),51]<-3 ; Policies[seq(50,75,5),51]<-4
Policies[seq(50,75,1),52]<-3 ; Policies[50,52]<-1
Policies[seq(50,75,1),53]<-3 ; Policies[55,53]<-1
Policies[seq(50,75,1),54]<-3 ; Policies[60,54]<-1
Policies[seq(50,75,1),55]<-3 ; Policies[65,55]<-1
Policies[seq(50,75,1),56]<-3 ; Policies[70,56]<-1
Policies[seq(50,75,1),57]<-3 ; Policies[75,57]<-1
Policies[seq(50,75,1),58]<-3 ; Policies[c(50,60),58]<-1
Policies[seq(50,75,1),59]<-3 ; Policies[c(55,65),59]<-1
Policies[seq(50,75,1),60]<-3 ; Policies[c(60,70),60]<-1
Policies[seq(50,75,1),61]<-3 ; Policies[c(65,75),61]<-1
Policies[seq(50,75,1),62]<-3 ; Policies[seq(50,75,10),62]<-1
Policies[seq(50,75,1),63]<-3 ; Policies[seq(55,75,10),63]<-1
Policies[seq(50,75,2),64]<-3 ; Policies[c(50,55),64]<-4
Policies[seq(50,75,2),65]<-3 ; Policies[c(55,60),65]<-4
Policies[seq(50,75,2),66]<-3 ; Policies[c(60,65),66]<-4
Policies[seq(50,75,2),67]<-3 ; Policies[c(65,70),67]<-4
Policies[seq(50,75,2),68]<-3 ; Policies[c(70,75),68]<-4
Policies[seq(50,75,2),69]<-3 ; Policies[seq(50,75,5),69]<-4
Policies[seq(50,75,2),70]<-3 ; Policies[50,70]<-1
Policies[seq(50,75,2),71]<-3 ; Policies[55,71]<-1
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Policies[seq(50,75,2),72]<-3 ; Policies[60,72]<-1
Policies[seq(50,75,2),73]<-3 ; Policies[65,73]<-1
Policies[seq(50,75,2),74]<-3 ; Policies[70,74]<-1
Policies[seq(50,75,2),75]<-3 ; Policies[75,75]<-1
Policies[seq(50,75,2),76]<-3 ; Policies[c(50,60),76]<-1
Policies[seq(50,75,2),77]<-3 ; Policies[c(55,65),77]<-1
Policies[seq(50,75,2),78]<-3 ; Policies[c(60,70),78]<-1
Policies[seq(50,75,2),79]<-3 ; Policies[c(65,75),79]<-1
Policies[seq(50,75,2),80]<-3 ; Policies[seq(50,75,10),80]<-1
Policies[seq(50,75,2),81]<-3 ; Policies[seq(55,75,10),81]<-1

SCRES<-matrix(0,81,22) #scenario matrix that has each scenario
#for (h in c(1:1)) { #for one scenario
for (h in c(41:81)) { #policy index
Scenario<-Policies[,h] # selecting the scenario

t<-1 #number of
load(file ="C:\\Users\\amirhosein.fouladi\\Dropbox\\LA
Tech\\Research\\Dessertation\\ACL\\Scenarios\\BRates20205000-4.RData") #importing
the set of parameters
dim(BRates2020)
#################Variables for calibration process
BERROR<-matrix(0,t,1) # sum of errors between seer and estimated incidence rates
BMSERROR<-matrix(0,t,1) #sum squared error recorder between seer and estimated
incidence rates
BIGRES<-matrix(0,t,18) # estimated incidence rates
BDIF<-matrix(0,t,18) # difference between each estimated and actual incidence rates
##################################################
SEER_Males<matrix(c(0,0,0,0.4,1.3,2.5,5.3,9.2,17.4,32.1,61.9,76.1,106.7,153.1,205.4,248.3,301.7,342.
7),18,1,dimnames = list(
c("0-4","5-9","10-14","15-19","20-24","25-29","30-34","35-39","4044","45-49","50-54","55-59","60-64","65-69","70-74","75-79","80-84","85+"),"Males"))
#SEER reported incidence rates

GDR<(matrix(c(5498,419,283,210,183,151,131,114,98,83,75,84,120,189,284,384,486,600,726,
856,990,
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1112,1203,1254,1277,1291,1309,1326,1348,1372,1399,1426,1454,1485,1521,1573,1642,
1723,
1813,1914,2027,2164,2332,2542,2795,3068,3366,3716,4116,4548,4989,5435,5901,6401,
6942,
7527,8140,8771,9406,10051,10736,11478,12273,13128,14057,15076,16204,17483,1892
3,20533,
22439,24653,27135,29737,32404,35321,38796,42852,47377,52749,58353,64396,71496,
79699,88491,
97689,109336,122073,135933,150930,167061,184300,202596,221873,242028,262931,2
84431,306354,
328515,350719),100,1))/1000000 #general death rates
CDR<(matrix(c(rep(0,4),rep(c(0,0,0,0.2,0.5,1.2,2.5,4.7,8.8,15.4,23.5,35.2,48.8,70.6,99.5,137.3,
213.4,213.4,213.4),each = 5),213.4),100,1))/10000 #CRC death rates
DR<-GDR-CDR #death rates based om any causes but CRC
ASDR<-matrix(c(rep(.0542,100),rep(0.1677,100),rep(0.6469,100)),100,3) #stage specific
CRC death rates
Utilities<-matrix(c(rep(.91,44),rep(c(.78,.77,.75),each=10),rep(0.73,26)),100,1,dimnames
= list(
c(1:100),c("Healthy State Life Expectancy"))) #Healthy State Life Expectancy
Disutilities<-matrix(c(0.0301,0.0027,0.0027,0.0055),4,1,dimnames =
list(c("Colonoscopy","FIT","FOBT","FS"),"Disutilities")) #test disutilities
DQ<-read.csv("C:\\Users\\amirhosein.fouladi\\Dropbox\\LA Tech\\Research\\CRCSimulation files\\Excel Files\\MD Anderson.csv",header = TRUE) # stage specific age
specific CRC life expectancy
TSen<matrix(c(c(.75,.85,.95,.95),.076,.076,.238,.74,.075,.124,.239,.7,.75,.85,.95,.95),4,4,dimna
mes =
list(c("Dimunitive","Medium","Large","CRC"),c("Colonoscopy","FIT","FOBT","FS")))
# Test sensitivities
TSpec<-matrix(c(.86,.898,.925,.87),4,1,dimnames =
list(c("Colonoscopy","FIT","FOBT","FS"),"Specifity")) # test specificity
FSF<-matrix(c(1,1,1,1),1,4) #a matrix to disable a test in ascenario (for testing the code)
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SojT<-matrix(c(rep(5.5,54),rep(c(5.5,5.2,4.7,4.9,5),each=5),rep(5.5,21)),100,1,dimnames
= list(
c(1:100),c("Sojourn Time"))) #mean Sojourn time
##Cost information
Price<-matrix(c(1192.6,24.88,24.88,548.47),4,1,dimnames =
list(c("Colonoscopy","FIT","FOBT","FS"),"Price")) # test prices
TRC<matrix(c(20247.20,1305.04,26007.5,2346.72,30085.20,15057,24544.13,1576.24),2,4,dim
names = list(c("Initial","Surveillance"),c("Local","Regional","Distant","Weighted
Average"))) #Treatment cost
########################################################################
###################
for(x in c(1:t)){#parameter set index
CC<-matrix(0,100,1) #new cancer cases
DC<-matrix(0,100,1) #death cases
AC<-matrix(0,100,1) #alive cancer cases
Rates<-BRates2020[,,4250] # importing different rates from an array
#############################
K<-100000 # of patients
n<-7 #maximum number of adenomas (one fewer than n)
######################################
BQALYs<-matrix(0,K,1) #QALYs recorde
BCosts<-matrix(0,K,1) # costs recorde
CQALYs<-matrix(0,K,1) # a test measure
CCosts<-matrix(0,K,1) # a test measure
FSR<-matrix(0,K,9) # a test measure
CSR<-matrix(0,100,3) # a test measure
PREC<-array(0,dim=c(100,9,K)) # a test measure
WQUALY<-matrix(0,100,K) # a test measure
WCOST<-matrix(0,100,K) # a test measure
for(k in c(1:K)){ #starting simulation of K patients
S<-matrix(c(0),100,9,byrow=TRUE,dimnames = list(c(1:100),c("AdenomaD","Adenoma-M","Adenoma-L","CRC-L","CRC-R","CRC-D","Alive?","Death
Cause","# OF Years With CRC"))) # patient life matrix
i<-1 #aging index
A<-0 #alive or dead index (0 is alive)

55
W<-0 # a test measure
QALYs<-0 #patinet QALYs recorder
Costs<-0 #patient Cost recorder
STF<-0 # Sojourn time flag
RST<-101 # sojourn time
CF<-0 #cancer flag to distinguish cancer cases from non cancer cases
while(i<=100 & A==0){ #start aging from 1 to 100 for a person
AQ<-0 #Adding QALYs permission
CR<-S[i,5] #number of CRC-R adenomas in this state
if(CR>=1){ #in case the patient have at least one CRC-R adenoma
for(u in c(1:CR)){ #counting adenoma
r5<-runif(1,0,1)
if(r5>Rates[(ceiling(i/5)),19]){ #56
S[i,5]<-S[i,5]-1
S[i,6]<-S[i,6]+1
CSR[c(i:100),3]<-CSR[c(i:100),3]+1
CSR[c(i:100),2]<-CSR[c(i:100),2]-1
}
u<-u+1 #next adenoma
}
}
CL<-S[i,4] #number of CRC-L adenomas in this state
if(CL>=1){ #in case the patient have at least one CRC-L adenoma
for(r in c(1:CL)){ #counting adenoma
r4<-runif(1,0,1)
if(r4>Rates[(ceiling(i/5)),17]){ #45
S[i,4]<-S[i,4]-1
S[i,5]<-S[i,5]+1
CSR[c(i:100),2]<-CSR[c(i:100),2]+1
CSR[c(i:100),1]<-CSR[c(i:100),1]-1
}
r<-r+1 #next adenoma
}
}
L<-S[i,3] #number of large adenomas in this state
if(L>=1){ #in case the patient have at least one large adenoma
for(o in c(1:L)){ #counting adenoma
r3<-runif(1,0,1)
if(r3<=Rates[(ceiling(i/5)),14]){ #stage 3 to 2
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S[i,3]<-S[i,3]-1
S[i,2]<-S[i,2]+1
}
if(r3>=(1-Rates[(ceiling(i/5)),16])){ #stage 3 to 4
if(S[i,4]==0){ #a test measure
CC[i]<-CC[i]+1
CSR[c(i:100),1]<-CSR[c(i:100),1]+1
SCRES[h,5]<-SCRES[h,5]+1 #a test measure
CF<-1 #a test measure
RST<-rexp(1,(1/SojT[i])) #generate mean sojourn time
if(STF==0){
S[i,9]<-1
STF<-1
}
}
S[i,3]<-S[i,3]-1
S[i,4]<-S[i,4]+1
}
o<-o+1 #next adenoma
}
}

M<-S[i,2] #number of medium adenomas in this state
if(M>=1){ #in case the patient have at least one medium adenoma
for(m in c(1:M)){ #counting adenoma
r2<-runif(1,0,1)
if(r2<=Rates[(ceiling(i/5)),9]){ #stage 2 to 1
S[i,2]<-S[i,2]-1
S[i,1]<-S[i,1]+1
}
if(r2>=(1-Rates[(ceiling(i/5)),11])){ #stage 2 to 3
S[i,2]<-S[i,2]-1
S[i,3]<-S[i,3]+1
}
m<-m+1 #next adenoma
}
}
D<-S[i,1] #number of dimunitive adenomas
if(D>=1){ #in case the patient have at least one dimunitive adenoma
for(l in c(1:D)){ #counting adenoma
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r1<-runif(1,0,1)
if(r1<=Rates[(ceiling(i/5)),4]){ #stage 1 to 0
S[i,1]<-S[i,1]-1
}
if(r1>=(1-Rates[(ceiling(i/5)),6])){ #stage 1 to 2
S[i,1]<-S[i,1]-1
S[i,2]<-S[i,2]+1
}
l<-l+1 #next adenoma
}
}

if(sum(S[i,])<n){ #checking the maximum allowed number of adenoma condition to
see if we can have adenoma incidence or not
r0<-runif(1,0,1)
f<-0
for(j in c((n-sum(S[i,])):1)){#number of adenoma that can be generated
if(r0<=(Rates[(ceiling(i/5)),2])^(j) & f==0){ #number of adenoma that the body
generates
S[i,1]<-S[i,1]+(j) #adding generated adenomas life matrix
f<-1
}
j<-j-1
}
}
if(i<=99){ #copying patient life matrix next year
S[i+1,]<-S[i,]
if(STF>0){
S[i+1,9]<-S[i,9]+1 ########add one to Sojourn time counter for next year
}
}
#############Applying screening tests
##########Removing adenomas via clonoscopy / a person with adenoma and not
cancer has colonoscopy
if(Scenario[i]==1 & sum(S[i,(4:6)])==0){ ## removing adenomas
SCRES[h,13]<-SCRES[h,13]+1
for(g in c(1:3)){ #to apply the test on Dimunitive,Medium and Large Adenoma
for(e in c(1:S[i,g])){ #to go one by one on each adenoma
r13<-runif(1,0,1)
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if(S[i,g]>0 & r13<=TSen[g,1]){
S[i+1,g]<-S[i+1,g]-1
CF<-1
}
}
}
}
##########Removing adenomas via FS / a person with adenoma and not cancer has
FS
if(Scenario[i]==4 & sum(S[i,(4:6)])==0){ ## removing adenomas
for(g in c(1:3)){ #to apply the test on Dimunitive,Medium and Large Adenoma
for(e in c(1:S[i,g])){ #to go one by one on each adenoma
r11<-runif(1,0,1)
r14<-runif(1,0,1)
if(S[i,g]>0 & r14<=TSen[g,4] & r11<=.34){
S[i+1,g]<-S[i+1,g]-1
CF<-1
}
}
}
}
######### A CRC case has Screening
r15<-runif(1,0,1)
if((sum(S[i,c(4:6)]))>0 & Scenario[i]>0){
if(r15<(FSF[Scenario[i]])){
TT<-Scenario[i] #to clarify test type
if(TT==1){
SCRES[h,13]<-SCRES[h,13]+1 # a measure test
}
r8<-runif(1,0,1)
if(r8<TSen[4,TT]){#True positive ,, terminating patient because we discover his
CRC
if(TT==2 | TT==3){ #deduct colonoscopy disutility and add colonoscopy
cost
QALYs<-QALYs-Disutilities[1] #extra colonoscopy
Costs<-Costs+Price[1]
SCRES[h,14]<-SCRES[h,14]+1# a test measure
}
S[c(i:100),7]<-i #setting the matrix life for the rest of the years to show age
at death and cause of dead
S[c(i:100),8]<-TT
SCRES[h,(TT+5)]<-SCRES[h,(TT+5)]+1 # a test measure
A<-1
# adding QALYS based on final stage of patient
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if(S[i,6]>0){ #distant
QALYs<-QALYs+DQ[(i),3]

Costs<-Costs+TRC[1,3]+TRC[2,3] #adding treatment costs
AQ<-1
}
if(S[i,5]>0 & AQ==0){ #regional
QALYs<-QALYs+DQ[(i),2]
Costs<-Costs+TRC[1,2]+TRC[2,2]
AQ<-1
}
if(S[i,4]>0 & AQ==0){ #localized
QALYs<-QALYs+DQ[(i),1]
Costs<-Costs+TRC[1,1]+TRC[2,1]
AQ<-1
}
}
#if we get False Negetive, patient will go back to system and his CRC may be
diagnosed later
}}
########### A healthy patient has Screening
if(sum(S[i,c(4:6)]==0 & Scenario[i]>0)){
TT<-Scenario[i]
r10<-runif(1,0,1)
if(r10 > TSpec[TT]){ # false positive
# colonoscopy and biopsy discover the truth ,, True Negetive
QALYs<-QALYs-.0027 #deducting disutility for the false positive
if(TT==2 | TT==3){ # if patient gest the false negative from FIT or FOBT
Costs<-Costs+Price[1] #extra colonoscopy
QALYs<-QALYs-Disutilities[1] #extra colonoscopy
SCRES[h,14]<-SCRES[h,14]+1 # a test measure

if(sum(S[i,(1:3)])>0){ ## removing adenomas in case the patient has adenoma ,
(lucky patient)
for(g in c(1:3)){ #to apply the test on Dimunitive,Medium and Large Adenoma
for(e in c(1:S[i,g])){ #to go one by one on each adenoma
r13<-runif(1,0,1)
if(S[i,g]>0 & r13<=TSen[g,1]){
S[i+1,g]<-S[i+1,g]-1
CF<-1
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}
}
}
}
}
}
if(TT==1){ #test is colonoscopy
SCRES[h,13]<-SCRES[h,13]+1 # a test measure
}
}
############################# Sojourn time and self detection
if(A==0 & S[i,9]>=RST){ #if cancer becoms symptomatic
### we add remaining QALYs and costs based on distant stage and terminate him
S[c(i:100),7]<-i
S[c(i:100),8]<-9
SCRES[h,10]<-SCRES[h,10]+1 # a test measure
A<-1
DC[i]<-DC[i]+1
# adding QALYS based on distant stage
QALYs<-QALYs+DQ[i,3]
Costs<-Costs+TRC[1,3]+TRC[2,3]
AQ<-1
}

########### terminating a CRC case before sojourn time
if(A==0 & S[i,6]>0){ #killing a distant case
r7<-runif(1,0,1)
if(r7<= ASDR[i,3]){
S[c(i:100),7]<-i #updating teh life matrix
S[c(i:100),8]<-6
SCRES[h,11]<-SCRES[h,11]+1 #a test measure
A<-1
DC[i]<-DC[i]+1
FSR[k,]<-S[i,]
CSR[c(i:100),3]<-CSR[c(i:100),3]-1 # a test measure
}
}
if(A==0 & S[i,5]>0){ #terminating a regional case
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r7<-runif(1,0,1)
if(r7<= ASDR[i,2]){
S[c(i:100),7]<-i #updating the life matirx
S[c(i:100),8]<-6
SCRES[h,11]<-SCRES[h,11]+1
A<-1
DC[i]<-DC[i]+1
FSR[k,]<-S[i,]
CSR[c(i:100),2]<-CSR[c(i:100),2]-1 #a test measure
}
}
if(A==0 & S[i,4]>0){ #killing a localized case
r7<-runif(1,0,1)
if(r7<= ASDR[i,1]){
S[c(i:100),7]<-i #updating the life matrix
S[c(i:100),8]<-6
SCRES[h,11]<-SCRES[h,11]+1 #a test measure
A<-1
DC[i]<-DC[i]+1
FSR[k,]<-S[i,]
CSR[c(i:100),1]<-CSR[c(i:100),1]-1
}
}
###########killing a non crc cases because of natural causes
r9<-runif(1,0,1)
if(r9<=DR[i] & A==0 & sum(S[i,(4:6)])==0){
S[c(i:100),7]<-i # updating the life matrix
S[c(i:100),8]<-10
SCRES[h,12]<-SCRES[h,12]+1 # a test measure
A<-1
DC[i]<-DC[i]+1
}
#######adding QALYs
if(AQ==0){#adding cost and QALYs for the patient
QALYs<-QALYs+Utilities[i,1]
AQ<-1
}
if(Scenario[i]>0){
QALYs<-QALYs - Disutilities[Scenario[i]]
Costs<-Costs+Price[Scenario[i]]
}
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#end of adding cost and QALYs for the patient
i<-i+1 #next year of the person's life
} # end of simulating a person
BQALYs[k]<-QALYs # recording this patient QALYs
BCosts[k]<-Costs # recording this patient cost
if(CF==1){ # a test measure
CQALYs[k]<-QALYs
CCosts[k]<-Costs
}
for (ab in c(1:100)){#a test measure
if (sum(S[ab,c(4:6)])>0){
AC[ab]<-AC[ab]+1
}
}
PREC[,,k]<-S # a test measure
k<-k+1 #next person
} #end of simulating K people
AP<-K-cumsum(DC) #Alive Population
########################################### Population Matrix
PO<-matrix(0,18,1)
for(i in c(1:16)){
PO[i+1]<-sum(AP[(5*i):(5*i+4)])
}
PO[1]<-sum(AP[1:4])
PO[18]<-sum(AP[85:100])
###########################################Cancer Cases Matrix
CCases<-matrix(0,18,1)
for(i in c(1:16)){
CCases[i+1]<-sum(CC[(5*i):(5*i+4)])
}
CCases[1]<-sum(CC[1:4])
CCases[18]<-sum(CC[85:100])
###########################################Final result
MRates<-matrix(0,18,1)
for(i in c(1:18)){
MRates[i]<-((100000*CCases[i])/(PO[i]))
}
Temp<-t(MRates)
BIGRES[x,]<-Temp[1,]
########################################### absolute Error and Square Error
between Seer and my rates
Difference<-matrix(0,18,1)
DifferenceS<-matrix(0,18,1)
for(i in c(1:18)){
Difference[i]<-((SEER_Males[i])-(MRates[i]))
DifferenceS[i]<-((SEER_Males[i])-(MRates[i]))^2
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}
ERROR<-sum(abs(Difference))
MSERROR<-sum(DifferenceS)
BERROR[x]<-ERROR
BMSERROR[x]<-MSERROR
BDIF[x,]<-t(Difference[,1])
########################################### gathering all row result in a matrix
and write it
Result<-cbind(AP,CC,AC)
colnames(Result)<-c("Population","New Cancer cases","Alive cancer cases")
###########################################Putting final results and SEER
together
COMP<-cbind(MRates,SEER_Males)
#COMP
###########################################
}#calibration ends
SCRES[h,1]<-mean(BQALYs) # patinets expected QALYs
SCRES[h,2]<-sd(BQALYs) # QALYs standard deviation
SCRES[h,3]<-mean(BCosts) # patinets expected costs
SCRES[h,4]<-sd(BCosts) # cost standard deviation
SCRES[h,15]<-mean(CQALYs[CQALYs!=0]) # test measures
SCRES[h,16]<-sd(CQALYs[CQALYs!=0]) # test measures
SCRES[h,17]<-mean(CCosts[CCosts!=0]) # test measures
SCRES[h,18]<-sd(CCosts[CCosts!=0]) # test measures
SCRES[h,19]<-K-length(which(BQALYs==0)) # test measures
SCRES[h,20]<-K-length(which(BCosts==0)) # test measures
SCRES[h,21]<-K-length(which(CQALYs==0)) # test measures
SCRES[h,22]<-K-length(which(CCosts==0)) # test measures
write.csv(SCRES,file = "C:\\Users\\amirhosein.fouladi\\Dropbox\\LA
Tech\\Research\\Dessertation\\ACL\\Scenarios\\SCRES10-1-27-41-81.csv")
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